ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2019 Earnings Conference Call - Final Transcript
Feb 14, 2020 • 08:00 am ET
Thank you. [Operator Instructions] Our first question comes from John Newman of Canaccord. Your line is now open.
Hey, good morning, guys. Thanks for taking the question. So, first of all, Anna and Mark, just curious if you could give us a rough sense as to the number of patients for the FORWARD II platinum-agnostic doublet that we might see mid year and I'm wondering if any of the patients within that group would have received prior Avastin therapy. Thanks.
So the -- yeah, sorry. So the cohort is 60 patients, and yes, a number of those patients will have received prior Avastin, I can't say that off the top of my head, how many that is.
Okay, great. And then just a quick question on SORAYA. I'm assuming that given in the U.S. getting reimbursement for more than one line of Avastin, it's been a little bit challenging until recently. I'm wondering if the patients in SORAYA will have just one prior line of therapy with Avastin or if you might have a few patients that would have more than one.
Thanks, John. So SORAYA is being enrolled in the U.S. as well as in Europe. And historically, typically, patients really only get one line of Avastin, if they do have access to it at all. And remember, this is patients with platinum-resistant disease with one to three priors. So the only data that I'm aware of really showing that Avastin after Avastin works is from the MITO/MANGO study where it was shown that after frontline treatment with an Avastin containing regimen, you still got benefit in the recurrent platinum-sensitive setting with another Avastin regimen. So we anticipate that very few patients will have had more than one prior line of Avastin.
Okay, great, thank you very much.
Thank you. And our next question comes from Biren Amin of Jefferies. Your line is now open.
Yeah, hi guys thanks for taking my questions. Anna, on the FORWARD II trial with the triplet, can you just maybe give us what the next steps are? I think, in 2019, you presented some data there in about 41 patients, saw a pretty strong response rates and DOR. How much additional data do you need to see before you move the triplet FORWARD into a pivotal study?
Yeah. So we will be presenting longer-term data from the triplet likely at ESMO this year, where we should have mature PFS data. You may recall that the benchmark for other triplets, so Carbo/ Gem BEV and Carbo/Pac BEV, there the median PFS is somewhere around 12 months to 14 months. Carbo/Doxil BEV also read out at ESMO last year, the year before also looking similarly. So those are -- those are the benchmarks. And so we'll see how our triplet stacks up in terms of PFS, as well as safety and tolerability and then we'll take it from there. Any potential registration option for that triplet would be a large long trial so where we'll